Peroxisome proliferator-activated receptor gamma (PPARγ) Ser273 phosphorylation (pSer273-PPARγ)

Peroxisome proliferator-activated receptor gamma (PPARγ) Ser273 phosphorylation is a specific post-translational modification mediated primarily by Cyclin-dependent kinase 5 (Cdk5) in response to obesity-induced inflammatory signals (Choi et al., 2010, Nature). This phosphorylation event does not alter the adipogenic activity of PPARγ but specifically dysregulates a subset of genes involved in insulin sensitivity, such as adiponectin and adipsin, leading to insulin resistance (Banks et al., 2015, Nature). Therapeutic strategies aim to inhibit this specific phosphorylation to treat type 2 diabetes and metabolic syndrome. Traditional thiazolidinediones (TZDs) like rosiglitazone effectively inhibit Ser273 phosphorylation, which contributes to their anti-diabetic efficacy, but they also act as full agonists, causing side effects like weight gain and fluid retention (Choi et al., 2010, Nature). Modern drug development focuses on non-agonist PPARγ ligands, such as SR1664, that selectively block Ser273 phosphorylation without triggering the full transcriptional program of the receptor (Kamenecka et al., 2013, J Med Chem). By preserving the expression of insulin-sensitizing genes while avoiding the side effects of classical agonists, targeting this modification represents a precision approach to metabolic disease therapy.

Other names

Cdk5-mediated PPARG Ser273 phosphorylationPhospho-Ser273 PPARγPPARγ Ser273 phosphorylationpSer273-PPARgammaPeroxisome proliferator-activated receptor gamma Ser273 phosphorylation

Inhibition of the phosphorylation of PPARγ at Ser273 by Cdk5 or other kinases (like ERK) to restore the expression of insulin-sensitizing genes without inducing full transcriptional activation associated with adipogenesis and side effects.